FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma

abnormalities on 18 F-FDG PET, sometimes in the absence of abnormalities on conventional radiological modalities. Rituximab is an important drug in the treatment of NHL patients; its withdrawal should, therefore, only be considered in symptomatic patients. RP proved to be reversible after discontinuation of rituximab in combination with administration of steroids or supportive care. More research has to be performed to confirm and quantify the association of rituximab and adverse lung reactions, to understand the underlying mechanism and to search for variables, predisposing for the development of RP.